Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Orphanet Journal of Rare Diseases|August 8, 2024
Pozelimab for CHAPLE disease: results from in-trial interviews and clinical outcome assessmentsLeighann Litcher-Kelly, Ahmet Ozen, Sarah Ollis, et al.
Clinical Pharmacology and Therapeutics|April 20, 2023
Regulatory and HTA Considerations for Development of Real-World Data Derived External ControlsLesley H Curtis, Oriol Sola-Morales, Julien Heidt, et al.
Orphanet Journal of Rare Diseases|February 11, 2025
The patient experience of CHAPLE disease: results from interviews conducted as part of a clinical trial for an ultra-rare conditionLeighann Litcher-Kelly, Ahmet Ozen, Sarah Ollis, et al.
European Journal of Haematology|May 9, 2025
Prognostic Factors and Effect Modifiers in Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma After Two Lines of Therapy: A Systematic Literature and Expert Clinical ReviewBastian von Tresckow, Pau Abrisqueta, Irene Zamanillo, et al.
The Journal of Allergy and Clinical Immunology|August 7, 2022
REGN1908/1909 prevented cat allergen-induced early asthmatic responses in an environmental exposure unitFrederic J de Blay, Alina Gherasim, Nathalie Domis, et al.
Annals of Hematology|September 2, 2025
Prognostic factors and effect modifiers in patients with relapsed or refractory follicular lymphoma who failed at least two lines of therapy: a systematic literature and expert clinical reviewPau Abrisqueta, Ana Jiménez-Ubieto, Ángel Serna, et al.
Circulation. Cardiovascular Quality and Outcomes|October 31, 2015
Relationship Between Physician and Hospital Procedure Volume and Mortality After Carotid Artery Stenting Among Medicare BeneficiariesJessica J Jalbert, Marie D Gerhard-Herman, Louis L Nguyen, et al.
JAMA Neurology|January 13, 2015
Outcomes after carotid artery stenting in Medicare beneficiaries, 2005 to 2009Jessica J Jalbert, Louis L Nguyen, Marie D Gerhard-Herman, et al.
Lancet (London, England)|January 26, 2024
Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 studyAhmet Ozen, Voranush Chongsrisawat, Asena Pinar Sefer, et al.
Blood Cancer Journal|April 1, 2026
Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United StatesShaji Kumar, Katja C Weisel, Paul Spin, et al.
Pageof 5